SFV VECTOR EXPRESSION SYSTEM - G. F. TEMPLE 
Life Technologies, Inc. 
Corporate Offices 
8400 Helgorivmn 
P.O. Box 6009 
M i.", ■ i ' ' i I’l 88.1 
] 840 8000 
July 15, 1993 
Nelson A. Wivel, M.D. 
Office of Recombinant DNA Activities 
National Institutes of Health, 31-4B11 
Bethesda, MD 20892 
Dear Dr. Wivel: 
I am enclosing for your Committee’s review a proposed version of a Users’ Manual that 
includes the information requested by RAC, on June 8, in response to our request to classify 
the Life Technologies SFV/Helper 2 Gene Expression System for use at Biosafety Level 2. 
In addition to information presented previously, this manual contains the following: 
A summary of potential health risks associated with use of the SFV/Helper 2 Gene 
Expression System (Section IB); 
A description of several practical and effective means to inactivate SFV present in 
liquid or on surfaces (Section IIIB), together with the experimental investigations and 
results that support the use of these methods (Appendix C); 
A simple protocol for detecting replication-competent SFV present in solutions or cell 
cultures (Section IIIC); 
A description of symptoms associated with SFV infection and procedures to be 
followed in the event that SFV infection occurs in a laboratory worker, including 
precautions to prevent interpersonal spread of SFV by mosquitos (Section IC); 
Warnings to abide by Biosafety Level 2 guidelines prominently posted on each page 
of those protocols in Section IIIA which might expose the worker to infectious virus- 
assuming that RAC classifies this vector system for use at BL 2; 
A Biosafety Clearance Agreement that must be signed by the user and his or her 
Institutional Biosafety Committee and received at Life Technologies, before the 
SFV/Helper 2 Gene Expression System will be shipped to a customer (Section IA); 
Recombinant DNA Research, Volume 18 
[443] 
